Company research

Medicus Pharma Ltd. Common Stock (MDCX) stock fundamentals

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatme

As of 2026-10-08

Exchange
XNAS
Sector
Healthcare
Industry
Drug Manufacturers - General

Company overview

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in Conshohocken, Pennsylvania.

Daily valuation snapshot

These values are from the stored daily market snapshot dated 2026-10-08. They are not a live quote.

Daily close (USD)$0.1
Market capitalization (USD)$6,438,104.16
Price / earnings (TTM)Not reported
Price / bookNot reported

Continue the research

Read public ownership disclosures separately from company fundamentals. Test a strategy against dated historical observations before evaluating its assumptions; a past result is not a live trading outcome.